 |
|
|
| |
SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS
|
| |
| |
CROI 2022 Feb 11-16
Carolyn Bolton Moore1, Edmund Capparelli2, Katherine Calabrese , Brookie M. Best , Shawn Ward , Cindy McCoig , Herta Crauwels , Allison Agwu , Pearl Samson4, Barbara Heckman4, Susan L. Ford8, Adeola Adeyeye9, Andres Camacho-Gonzalez10, Jack Moye11, Aditya H. Gaur12
1Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 2University of California San Diego, La Jolla, CA, United States, 3FHI 360, Durham, NC, United States, 4Frontier Science & Technology Research Foundation, Inc, Amherst, NY, United States, 5ViiV Healthcare, Collegeville, PA, United States, 6Janssen Research & Development, Beerse, Belgium, 7The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 8GlaxoSmithKline, Research Triangle Park, NC, United States, 9National Institute of Allergy and Infectious Diseases, Baltimore, MD, United States, 10Emory University, Atlanta, GA, United States, 11National Institute of Child Health and Human Development, Bethesda, MD, United States, 12St Jude Children's Research Hospital, Memphis, TN, United States
|
| |
|
|
|
|
|
